Skip to content
Triangle logo TriangleGet started
← Study library

NCT01336933 · REGISTRY CONDITION SEARCH

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2023-09-22

This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Complete Response Rate of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) and Pralatrexate (P) Treatment

→

outcome · POSTED

Overall Response Rates (ORR)= (Complete Response Rates (CR) + Partial Response Rates (PR))

→

outcome · POSTED

Event Free Survival (EFS)

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

To Evaluate the Safety and Tolerability of the Regimen by the Percent of Participants With Indicated Adverse Events

→

outcome · POSTED

Percent of Patients Who Proceeded With Transplant

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically confirmed new diagnosis of Stage II, III and IV peripheral T-cell NHL not otherwise specified (NOS), anaplastic large cell lymphoma (ALK negative) (ALK positive if international prognostic index \[IPI\] 3, 4, or 5), angioimmunoblastic T-cell lymphoma, enteropathy associated T-cell lymphoma, hepatosplenic gamma delta T-cell lymphoma * Pathology material (hematoxylin and eosin \[H\&E\] stain, immunohistochemistry \[IHC\] and pathology report from initial diagnosis, if slides are not available, then 8 unstained slides of 4 micron thickness or a representative block should be sent) will be reviewed, and the diagnosis confirmed by University Nebraska Medical Center (UNMC) pathology department (retrospective diagnostic review: treatment may commence prior to the UNMC review) * No prior therapy with the exception of prior radiation therapy and 1 cycle of chemotherapy based on current diagnosis and clinical condition * Age 19 years or older (the age of consent in Nebraska); age 18 years or older (applicable to states where the age of majority is 18) * Expected survival duration of \>= six months * Karnofsky Performance Status \>= 70 * Absolute neutrophil count (ANC) \>= 1000 cells/mm\^3, unless due to lymphoma involvement of the bone marrow * Platelet Count \>= 100 mm\^3, unless due to lymphoma involvement of the bone marrow * Total bilirubin =\< 1.5 x upper normal limit (ULN), or =\< 3 x ULN if documented hepatic involvement with lymphoma, or =\< 5 x ULN if history of Gilbert's Disease * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x ULN (=\< 5 x ULN if documented hepatic involvement with lymphoma) * Serum potassium within normal range * Serum creatinine \< 2.0 mg/dL or calculated creatinine clearance (CrCl) \> 45 mL/min * Prothrombin time (PT) or international normalized ratio (INR), and partial thromboplastin time (PTT) =\< 1.5 x ULN unless patient is receiving anticoagulants; if patient is on anticoagulation therapy, levels should be within therapeutic range * Patients with measurable disease; patients with non-measurable but evaluable disease may be eligible after discussion with the principal investigator (PI); baseline measurements and evaluations must be obtained within 6 weeks of registration to the study; abnormal positron emission tomography (PET) scans will not constitute evaluable disease, unless verified by computed tomography (CT) scan or other appropriate imaging * Patients with measurable disease must have at least one objective measurable disease parameter; a clearly defined, bidimensionally measurable defect or mass measuring at least 2 cm in diameter on a CT scan will constitute measurable disease; proof of lymphoma in the liver is required by a confirmation biopsy * Women must not be pregnant or breast-feeding due to teratogenic effects of chemotherapy * All females of childbearing potential must have a blood test within 2 weeks prior to registration to rule out pregnancy * Pregnancy testing is not required for post-menopausal or surgically sterilized women * Male and female patients of reproductive potential must agree follow accepted birth control measures * Patient must be able to adhere to the study visit schedule and other protocol requirements * Patients must be willing to give written informed consent, and sign an institutionally approved consent form before performance of any study-related procedure not part of normal medical care; with the exception of 1 cycle of chemotherapy based on current diagnosis and clinical condition, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care * No serious disease or condition that, in the opinion of the investigator, would compromise the patient's ability to participate in the study Exclusion Criteria: * Pregnant or breast feeding females * Known positive for human immunodeficiency virus (HIV), human T-lymphotropic virus type 1 (HTLV-1), or infectious hepatitis, type A, B or C or active hepatitis * Major surgery within 2 weeks of study drug administration * Prior malignancies within the past 3 years with exception of adequately treated basal cell, squamous cell skin cancer, or thyroid cancer; carcinoma in situ of the cervix or breast; prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen (PSA) levels * Patients with a diagnosis of other peripheral T-cell lymphoma (PTCL) histologies other than those specified in the inclusion criteria * Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment * Any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent * Concomitant administration of nonsteroidal anti-inflammatory drugs (NSAIDs) and trimethoprim/sulfamethoxazole will not be allowed, since these may result in delayed clearance of pralatrexate
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    "A" Treatment: Cyclophosphamide,Etoposide, Vincristine and Prednisone (CEOP) "B" Treatment: Pralatrexate (P) "A" cycles (CEOP) of the treatment regimen are 14 days, followed by " B" cycles (P) which are 21 days, followed by 7 days of rest for a total of 42 days per course, unless criteria are met for stopping or holding treatment or to a maximum of 6 courses. Patients with Complete Response (CR) or Partial Response (PR), per investigators discretion, may then undergo hematopoietic stem cell collection and administration of standard preparative regimen followed by hematopoietic stem cell transplantation.
    intervention Names
    1. Drug: prednisone
    2. Drug: cyclophosphamide
    3. Drug: etoposide
    4. Drug: Vincristine
    5. Drug: pralatrexate
    6. Other: laboratory biomarker analysis
    7. Genetic: comparative genomic hybridization
    8. Genetic: gene expression analysis
    9. Genetic: nucleic acid sequencing
    10. Genetic: mutation analysis
    11. Other: immunohistochemistry staining method
    12. Genetic: microarray analysis
    label
    Treatment
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment
    description
    Given PO
    name
    prednisone
    other Names
    1. DeCortin
    2. Deltra
    type
    DRUG
  2. arm Group Labels
    1. Treatment
    description
    Given IV
    name
    cyclophosphamide
    other Names
    1. CPM
    2. CTX
    3. Cytoxan
    4. Endoxan
    5. Endoxana
    type
    DRUG
  3. arm Group Labels
    1. Treatment
    description
    Given PO or IV
    name
    etoposide
    other Names
    1. EPEG
    2. VP-16
    3. VP-16-213
    type
    DRUG
  4. arm Group Labels
    1. Treatment
    description
    Given IV
    name
    Vincristine
    other Names
    1. leurocristine sulfate
    2. VCR
    3. Vincasar PFS
    type
    DRUG
  5. arm Group Labels
    1. Treatment
    description
    Given IV
    name
    pralatrexate
    other Names
    1. FOLOTYN
    2. PDX
    type
    DRUG
  6. arm Group Labels
    1. Treatment
    description
    Correlative studies
    name
    laboratory biomarker analysis
    type
    OTHER
  7. arm Group Labels
    1. Treatment
    description
    Correlative studies
    name
    comparative genomic hybridization
    other Names
    1. comparative genomic analysis
    type
    GENETIC
  8. arm Group Labels
    1. Treatment
    description
    Correlative studies
    name
    gene expression analysis
    type
    GENETIC
  9. arm Group Labels
    1. Treatment
    description
    Correlative studies
    name
    nucleic acid sequencing
    other Names
    1. Gene Sequencing
    2. Molecular Biology, Nucleic Acid Sequencing
    type
    GENETIC
  10. arm Group Labels
    1. Treatment
    description
    Correlative studies
    name
    mutation analysis
    type
    GENETIC
  11. arm Group Labels
    1. Treatment
    description
    Correlative studies
    name
    immunohistochemistry staining method
    other Names
    1. immunohistochemistry
    type
    OTHER
  12. arm Group Labels
    1. Treatment
    description
    Correlative studies
    name
    microarray analysis
    other Names
    1. gene expression profiling
    type
    GENETIC
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
34
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Complete Response Rate (CR) was reported at the end of the CEOP-P (6 courses for patients not receiving transplant and 4-6 courses for patients receiving transplant). Response assessment was performed by computerized tomography (CT) or positron emission tomography (PET)/CT based on the investigator's preference after cycles 2, 4 and 6. Response was assessed by the treating physician according to the Cheson Revised response criteria (Cheson et al,, 2007) or International Harmonization Project criteria (Cheson, 2007), based on imaging modality used. Complete Response Definition: Disappearance of all evidence of disease Nodal Masses: (a) \[18F\]fluorodeoxyglucose(FDG)-avid or PET positive prior to therapy; mass of any size permitted if PETnegative (b) Variably FDG-avid or PET negative; regression to normal size on CT Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative
    measure
    Complete Response Rate of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) and Pralatrexate (P) Treatment
    time Frame
    168 days - 252 days (4-6 courses; 42 days per course)
secondary Outcomes
  1. description
    Every patient who fulfills all aspects of patient eligibility who receives at least 2 complete courses of chemotherapy will be evaluable for the response endpoint. Response rates will be descriptively summarized using percentages and 95% confidence intervals. Complete Response Definition: Defined in Primary Objective Partial Response Definition: Regression of measurable disease and no new sites, Nodal Masses: \> 50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes 1. FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site 2. Variably FDG-avid or PET negative; regression on CT Spleen, Liver:\> 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified
    measure
    Overall Response Rates (ORR)= (Complete Response Rates (CR) + Partial Response Rates (PR))
    time Frame
    2 years
  2. description
    Estimated 2-year Event Free Survival (EFS), as well as plots of EFS, will be produced using the method of Kaplan-Meier, along with 95% confidence intervals for EFS. Event-free survival is defined as time from therapy until relapse, progression, or death from any cause.
    measure
    Event Free Survival (EFS)
    time Frame
    2 years
  3. description
    Estimated 2-year Overall Survival (OS), as well as plots of OS, will be produced using the method of Kaplan-Meier, along with 95% confidence intervals for OS. Overall survival is defined as time from the first chemotherapy administered on trial until death from any cause.
    measure
    Overall Survival (OS)
    time Frame
    2 years
  4. description
    Adverse events will be summarized using patient level incidence rates so that a patient contributes once to any adverse event. The number and percentage of patients with any adverse event will be summarized for each course. Serious adverse events will be analyzed similarly.
    measure
    To Evaluate the Safety and Tolerability of the Regimen by the Percent of Participants With Indicated Adverse Events
    time Frame
    22 months
  5. description
    Percentage of patients who received consolidation with high dose therapy and autologous stem cell rescue (HDT/SCR).
    measure
    Percent of Patients Who Proceeded With Transplant
    time Frame
    168-252 days (4 courses up to 6 courses of treatment)
Full study description
brief Summary
This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing
detailed Description
PRIMARY OBJECTIVES: I. To evaluate in a Phase II study a preliminary estimate of the complete response (CR) rate of a new chemotherapy regimen involving Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) alternating with Pralatrexate (P) as front line therapy for patients with Stage II, III and IV Peripheral T-Cell NHL not otherwise specified (NOS), Anaplastic large cell lymphoma (ALK negative), Angioimmunoblastic T-cell lymphoma, Enteropathy associated T-cell lymphoma, Hepatosplenic gamma delta T-cell lymphoma followed by an optional stem cell transplant with high dose chemotherapy and Autologous stem cell transplant. SECONDARY OBJECTIVES: I. To evaluate partial response (PR). II. To evaluate overall response (CR+PR). III. To evaluate the safety and tolerability of the regimen IV. To assess the 2 year event free survival (EFS) and overall survival (OS) using this regimen. V. To assess the percentage of patients who proceeded with transplant. VI. To evaluate the ability to collect peripheral blood stem cells after this regimen. OUTLINE: Patients receive cyclophosphamide intravenously (IV) and vincristine IV on day 1, etoposide IV on days 1-3 or orally (PO) once daily (QD) on days 2-3, and prednisone PO QD on days 1-5 (CEOP administration). Patients also receive pralatrexate IV over 3-5 minutes on days 15, 22, and 29 (P administration). Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with Complete Response (CR) or Partial Response (PR), per investigators discretion, may then undergo hematopoietic stem cell collection and administration of standard preparative regimen followed by hematopoietic stem cell transplantation. After completion of study treatment, patients are followed up for 2 years (transplant patients) or periodically.
Source references
references
  1. citation
    Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose JM. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016 Feb;172(4):535-44. doi: 10.1111/bjh.13855. Epub 2015 Dec 2.
    pmid
    26627450
    type
    BACKGROUND
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-2610cd17e62c2fd9ccd2
      requested nct id
      NCT01336933
      primary nct id
      NCT01336933
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      payload sha256
      a35307e2a86e66de0501b2ccb8005ae77e71c3f3dd53006e1d8476150540bd92
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-2610cd17e62c2fd9ccd2
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01336933
      occurrences
      1. context exact
        NCT01336933
        end
        11
        exact text
        NCT01336933
        start
        0
      offset unit
      unicode_code_points
      query cond
      Peripheral T-Cell Non-Hodgkin Lymphoma
      query disease state id
      ds-peripheral-t-cell-non-hodgkin-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      source json pointer
      /studies/22/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      2138af0f8e5ba7da11d071a2e7f49c7437c9eddb27c55780a1f53241e824011d

    Preserved source evidence · Not medical advice